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"TB is the child of poverty - and also its parent and provider",  
Archbishop Desmond Tutu, in this quote  
encapsulated the link between tuberculosis (TB) and poverty! 
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ABSTRACT 
Tuberculosis (TB) is at epidemic levels in the resource-limited settings (RLSs) due to 
HIV/AIDS, poverty and insufficient TB control programmes. These factors are also 
contributing to TB drug resistance. Patients with multidrug drug resistant tuberculosis (MDR-
TB) do not respond to first line drugs. These patients require unique drug regimens, making it 
necessary to routinely screen for MDR-TB. Screening for MDR-TB with the Lowenstein-
Jensen proportion method (LJPM), which is common in the RLSs is a very slow process – 
taking 2-3 months. More rapid tests suitable for RLSs are urgently needed. In this thesis, a 
comparison of the technical and operational performance of several rapid tests for MDR-TB 
was done, and the most optimal tests for RLSs are proposed.  
In paper I, a meta-analysis of rapid tests for direct detection of MDR-TB was conducted. The 
direct nitrate reductase assay (NRA), microscopic observation drug susceptibility (MODS) and 
Genotype® MTBDRplus (GT-DRplus) were highly sensitive and specific, and far more rapid 
than the conventional indirect drug susceptibility testing (DST).  
In paper II, the NRA, MODS, Mycobacterium Growth Indicator Tube (MGIT 960), GT-
DRplus, Alamar blue, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
and resazurin assays were compared head-to-head for indirect detection of MDR-TB at the 
National Tuberculosis Reference Laboratory (NTRL) Kampala. The NRA, MGIT 960, GT-
DRplus and MODS were the most sensitive and specific tests, with significantly shorter time to 
results compared to the LJPM.  
In paper III, the direct NRA and MODS assays were compared at the NTRL on consecutive 
sputum specimens from re-treatment TB patients. Interpretable results were obtained in over 
90% of the samples with both assays. The median days to results were 10 with the NRA and 7 
with MODS. The direct NRA was more sensitive and specific, and was cheaper.  
In paper IV, the sensitivity, specificity, time to results (TTR) and reproducibility of the direct 
GT-DRplus against the MGIT 960 was assessed. Sensitivity and specificity were 100% and 
96% for detection of rifampicin resistance; 81%, and 100% for isoniazid resistance; and 92%, 
and 96%, for MDR-TB, respectively. The TTR was 1-3 days, and concordance of results 
between the Molecular Laboratory at Makerere University and the FIND Diagnostics 
Laboratory was 98%.  
In paper V, we applied spoligotyping to study the clustering rate and predominant genotypic 
strains of 99 MDR-TB strains isolated from patients in Kampala.  Eighty three percent of the 
strains occurred in clusters, and the T2 lineage was the largest single cluster. 
Conclusion. The direct NRA and the GT-DRplus appear to be the most appropriate tests for 
MDR-TB in RLSs. The NRA being the cheapest test can be applied where resources are 
extremely limited, while the ultra rapid but commercially available GT-DRplus can be used 
where resources permit.   
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1 INTRODUCTION 
 
1.1 BACKGROUND 
The discovery of anti-TB drugs in the 1940s followed by combination chemotherapy 
made TB a curable disease. In the developed countries, effective treatment and 
surveillance reduced tuberculosis dramatically with high hopes of total eradication (1-
2). However, in the 1980s, it was realized that tuberculosis had not only ceased to 
decline in the developed countries, notably the USA, but was actually increasing, 
particularly in major cities (2). It was also soon realized that the disease was out of 
control and increasing at an alarming rate across most of the poorest regions of the 
world especially Africa due to HIV/AIDS (1, 3).  Presently, the  WHO  estimates that 
one-third of the world’s population is infected with Mycobacterium tuberculosis 
(MTB) - the bacterium that causes tuberculosis, and 9 million new cases of active TB 
and 2-3 million deaths occur  annually – 95% in developing countries (4-5).  
 
Global efforts to control the TB pandemic have been undermined by the emergence and 
spread of strains that are resistant to the commonly used first line anti-TB drugs 
isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z). Strains resistant to 
at least H and R, the two most efficacious TB drugs are termed multi drug resistant 
(MDR) (6). MDR-TB treatment is rather complicated as it requires second line drugs 
some of which are only injectables, are less efficacious, more toxic and more expensive 
than the first line agents (7). Treatment lasts for 18-24 months but only around 50% –
60% of MDR-TB patients will be cured compared with 95%–97% cure rate for patients 
with drug-susceptible strains treated with first line agents (8-9). The recent emergency 
of extensively drug resistant tuberculosis (XDR-TB) defined as MDR-TB strains with 
resistance to a fluoroquinolone and to at least one injectable second line drug 
(kanamycin, amikacin, or capreomycin) has further complicated the problem of MDR-
TB (6).  A study in South Africa found a mortality rate from XDR-TB of 90% among 
the HIV infected patients due to lack of treatment options (10).   
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1.2 EPIDEMIOLOGY OF MDR-TB  
The Global Project on Anti-Tuberculosis Drug Resistance Surveillance has been 
gathering data since 1994. The latest data indicates that every region of the world has 
reported MDR-TB, as shown in figure 1 (11).   
 
Figure 1. Proportion of MDR-TB among previously treated TB cases, 1994–2009 
Source: World Health Organization (11) 
 
1.2.1 MDR-TB Prevalence 
 
The number of prevalent cases of MDR-TB in many parts of the world is estimated to 
be much higher than the number of incident case arising annually. Globally, the 
median prevalence of MDR-TB is reported to be 3% among the new and 15% among 
the re-treatment cases (12). Countries and territories in Eastern Europe such as 
Tajikistan, Uzbekistan and parts of China have the highest MDR-TB prevalence – up to 
15% among the new and 60% among the previously treated cases (13). In sub Saharan 
Africa, inadequacy of laboratory services makes it difficult to estimate the actual 
burden of MDR-TB.  However, surveillance data (2005-7) from Cote d’Ivoire, 
Ethiopia, Madagascar, Rwanda, and Senegal, reported a prevalence of 1-4% among the 
new and 4-17% among the previously treated  TB cases (12). In Uganda, according to 
the first MDR-TB surveillance study done in 1996-7,  a prevalence of 0.5% among the 
new and 4% among the previously treated cases was reported (14). Temple et al (2008) 
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found MDR-TB in 13% of the previously treated cases at Kampala (15).  A more recent 
survey conducted in Kampala, found MDR-TB in 1.5% and 13% among the new and 
re-treatment cases, respectively (Joloba ML 2009, personal communication). These 
data indicate that if immediate control measures including improvements in laboratory 
infrastructure are not done, MDR-TB will be increasing dramatically in many African 
countries including Uganda.   
 
1.2.2 MDR-TB Incidence  
The estimated global number of incident MDR-TB cases among new and relapse TB 
cases in 2008 was 440 000 ((95% CI: 390 000–510 000) (16). Based on incident 
MDR cases, the WHO and the Stop TB Partnership identified 27 high MDR-TB 
burden countries responsible for 85% of the global estimated burden of MDR-TB. 
These countries refer to those Member States estimated by WHO in 2008 to have had at 
least 4000 MDR-TB cases arising annually and/or at least 10% of newly registered TB 
cases with MDR-TB (16). The countries are: Armenia, Azerbaijan, Bangladesh, 
Belarus, Bulgaria, China, Democratic Republic of the Congo, Estonia, Ethiopia, 
Georgia, India, Indonesia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Myanmar, 
Nigeria, Pakistan, Philippines, Republic of Moldova, Russian Federation, South Africa, 
Tajikistan, Ukraine, Uzbekistan and Viet Nam. China and India account for almost 
50% of the estimated global number of incident MDR-TB cases (16).  
 
Due to the limitations in susceptibility testing in many countries, it is believed that the 
true magnitude of the MDR-TB problem in the World is larger than currently known 
(12).  According to the Stop TB Partnership’s Global Plan to Stop TB, 2006–2015, an 
estimated 1.3 million MDR-TB cases will need to be treated in the 27 high MDR-TB 
burden countries between 2010 and 2015 alone, at an estimated total cost of US$ 16.2 
billion.  
 
1.2.3 Risk factors for MDR-TB 
 
Exposure to anti-TB drugs.  All worldwide drug surveys show that prior exposure to 
anti-TB drugs is the commonest risk factor for drug resistance (12, 16). Exposure to 
TB drugs helps to select for the pre-existing resistant mutant strains of M. 
tuberculosis in the patient, which then dominate the lesions.  
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HIV infection. Upcoming evidence suggests a possible association between HIV and 
MDR-TB. MDR-TB has been widely documented in nosocomial and other 
congregate settings among people living with HIV (10, 17-18). The 4th report on 
anti-tuberculosis drug resistance also reported a significant association between HIV-
positive status and MDR-TB in Latvia and Donetsk Oblast of Ukraine (16). 
Furthermore, in Lithuania HIV-positive TB patients had an 8.4 (95% CI: 2.7– 28.2) 
times higher odds of harboring MDR-TB strains than TB patients for whom HIV 
status was unknown (16). Lastly, preliminary results of a survey conducted in 
Mozambique in 2007 have also found a significant association between HIV and 
MDR-TB(16).  
 
Gender. While males predominate among TB cases in the World, an association 
between gender with MDR-TB has been controversial. Studies in South Africa, 
Australia, the Netherlands and the United States of America have reported slightly 
higher odds ratios among females than males, while other studies fail to find such 
associations (16). In general, it appears that the overall risk of harbouring MDR-TB 
strains is not influenced by gender.   
 
To summarise this section, among all the factors studied so far, prior exposure to anti-
tuberculosis drugs is the most important risk factor for MDR-TB. 
 
1.3 ANTI-TUBERCULOSIS DRUGS 
There was no known anti-TB chemotherapy until the 1940s. In that decade, 
streptomycin and p-aminosalicylic acid (PAS) were introduced as anti-TB drugs (19-
21). The key steps that heralded the development of modern TB chemotherapy 
however were the demonstration in clinical trials, in 1947-48, that streptomycin was a 
viable drug for the disease (21). Several drugs have since been discovered and as of 
today, anti-TB drugs can be broadly categorized into 2 groups based on clinical uses, 
namely (i) first line and (ii) second line drugs. First-line drugs are used in treatment of 
new TB cases in whom the risk of resistant TB is low, and are usually given orally. 
Second line drugs are used for treatment of TB that is resistant to first line drugs, and 
can be further categorised into 4 subgroups, i.e. injectable second line drugs, 
fluoroquinolones, oral bacteriostatic anti-TB agents and anti-tuberculosis agents with 
unclear efficacy - not recommended by WHO for routine use in MDR-TB patients 
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(22-23). Table 1 shows examples under each of these drug groups, the doses, 
mechanism of action and the genes affected by resistant mutations. 
Table 1.  Anti-TB drugs, action and genes affected by resistant mutations 
 
Drug Mechanism of action  Genes affected by 
resistant mutations 
First line drugs (Oral)  
Isoniazid (H) Inhibits mycolic acid synthesis katG, HA, oxyR 
Rampin (R) Binds to RNA polymerase inhibiting RNA synthesis   rpoB 
Pyrazinamide (Z) Activated to pyrazinoic acid, which is bacterialcidal  pncA 
Ethambutol (E) Inhibits cell wall synthesis. EA,B,C 
Second line drugs  
a. Injectable drugs  
Streptomycin (S) Binds to ribosomal proteins and Inhibits protein synthesis rrs, rpsl 
Amikacin (Am) Disrupts ribosomal function and Inhibits protein synthesis rrs, rpsl 
Kanamycin (Km) Binds to 30S ribosomal subunit, Hibiting protein 
synthesis  
rrs, rpsl 
Capreomycin (Cm) Similar to aminoglycosides rrs, rpsl 
b.  Fluoroquinolones   
Ciprofloxacin (Cfx) 
Ofloxacin (Ofx) 
Levofloxacin (Lfx) 
Moxifloxacin (Mfx) 
Gatifloxacin (Gfx) 
Disrupts the DNA-DNA gyrase complex blocking DNA 
synthesis 
gyrA, gyrB 
c.  Oral bacteriostatic anti-TB agents  (second-line)  
Cycloserine (Cs) Inhibits cell wall synthesis - 
Ethionamide (Eto) Inhibits oxygen dependent mycolic acid synthesis - 
P-aminosalicylic acid 
(PAS) 
Disrupts folic acid metabolism. - 
Rifabutin Binds to RNA polymerase Hibiting RNA synthesis   rpoB 
Thioacetazone (Th)   
d.  Anti-TB agents with unclear efficacy   
Clofazimine (Cfz) - - 
Amoxicillin/Clavulan
ate (Amx/Clv) 
- - 
Clarithromycin (Clr) - - 
Linezolid (Lzd) - - 
 
 
Isoniazid (H)  
 
Discovery. In 1912, Hans Meyer and Josef Mally first synthesized isonicotinic acid 
hydrazide (H) from ethyl isonicotinate and hydrazine as part of their research work at 
German Charles University in Prague (24). The chemical structure of isoniazid is 
shown in figure 2.  
 
Figure 2. Chemical structure of isoniazid (H) 
 10 
 
However, the antituberculosis properties of H were unveiled in the late 1940s when 
investigations at pharmaceutical companies Hoffman La Roche, Farbenfabriken Bayer, 
and Squibb Institute for Medical Research each independently discovered H as an 
antituberculosis agent (25). The efficacy of the drug was proved beyond doubt after a 
clinical trial in 1951-52 at Sea View Hospital in Staten Island, New York (26).  In 
1959, H and the earlier discovered streptomycin, later joined by R established a 
standard combined and effective drug regimen termed triple therapy at the time, for 
treatment against tuberculosis. A cure for tuberculosis was thus first considered 
reasonable.  
 
Mechanism of action. Isoniazid is a prodrug, and must be activated by a bacterial 
catalase-peroxidase enzyme (KatG), but the actual form of H that is active in vivo 
remains elusive (27). However, it is believed that KatG couples the isonicotinic acyl 
with NADH to form isonicotinic acyl-NADH complex and other yet unknown 
inhibitors (28). These inhibitors bind tightly to their targets, an enoyl-acyl carrier 
protein reductase (InhA) (29-30) and a β-ketoacyl-acyl carrier protein synthase (31). 
This process inhibits the synthesis of mycolic acid, a long chain fatty acid-containing 
component of the mycobacterial cell wall (32-34).   
 
Molecular Mechanism of resistance. Soon after introduction of H, it was realized that 
H-resistant MTB strains frequently lost catalase and peroxidase activity (35). In the 
1990’s the primary mycobacterial catalase-peroxidase gene (katG) was cloned and 
sequenced, and mutations in this gene were found in 42–58% of H-resistant clinical 
isolates, confirming the role of the KatG enzyme in H activity (27). A large number of 
different mutations have been characterized since then. However, the Ser315Thr 
mutation is found most often, occurring in approximately 40% of all isoniazid-resistant 
strains (36-38). The Ser315Thr mutation results in a catalase enzyme that cannot 
activate isoniazid, but retains approximately 50% of its catalase-peroxidase activity 
sufficient to enable the organism to detoxify host antibacterial radicals (39).  
 
M. tuberculosis with low level H resistance have been found to also have mutations in 
the promoter regions, or less commonly in the genes inhA, acpM, and kasA that 
respectively encode for the mycolic acid-synthesis intracellular proteins:  fatty-acid 
enoyl-acyl carrier protein reductase (InhA), acyl carrier protein (AcpM) and a β-
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ketoacyl-ACP synthase (KasA) (8). It is proposed that over-expression of one or more 
of these target proteins may be the reason for isoniazid resistance in these strains. 
Mutations in the promoter region of a gene that encodes an alkyl hydroperoxidase 
reductase (ahpC) have been found in approximately 10% of isoniazid-resistant isolates, 
but mutations in katG were also found in these isolates [8,16,23]. The resulting over-
expression of alkyl hydroperoxidase reductase may compensate for the loss of catalase-
peroxidase activity in these mycobacteria [24]. 
 
 
Rifampicin (R)  
Discovery. In 1957, Prof. Piero Sensi and colleagues at the Dow-Lepetit Research 
Laboratories in Milan, Italy discovered a new bacterium Nocardia mediterranei 
(formerly Streptomyces mediterranei) in a sample of soil from a pine wood on the 
French Riviera (40-42). This new species appeared immediately of great scientific 
interest since it was naturally producing a new class of molecules with antibiotic 
activity. These molecules were named "Rifamycins", in memory of the then popular 
French crime story Rifi - about a jewel heist and rival gangs (43). Several Rifamycins 
were characterized but subsequent studies leading to highly active derivatives were 
performed on Rifamycin B that was itself practically inactive. After two years of 
attempts to obtain more stable semi-synthetic products, in 1959 a new molecule with 
high efficacy and good tolerability was produced and was named "rifampicin" (40), 
whose chemical structure is shown in figure 3.  
 
 Figure 3. Chemical structure of rifampicin (R) 
 
Thus, R is a semisynthetic bactericidal antibiotic drug of the rifamycin group. 
Rifampicin was introduced for clinical use in 1967 as a major addition to the cocktail-
drug treatment of tuberculosis and meningitis, along with isoniazid, ethambutol, 
pyrazinamide and streptomycin (44). 
 
Mechanism of action. Rifampicin acts by binding to the beta subunit of the DNA-
dependent RNA polymerase. During transcription, DNA enters through the jaw side of 
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the RNA polymerase and both the DNA and the new RNA strands get out at the exit 
channel, as shown in figure 4 (45).  Rifampicin binds to the exit end of the RNA 
polymerase in bacterial cells and directly blocks the channel of the elongating RNA 
when the transcript becomes 2 to 3 nucleotides  long (46). This inhibits transcription of 
DNA to RNA and subsequent translation to proteins (45, 47).  
 
  
Figure 4. Crystal Structure of the RNA polymerase enzyme 
 
The human RNA polymerase variant is not affected by rifampicin even at 10 times the 
ininhibitory concentration in mycobacteria (47). The rifampicin-RNA polymerase 
complex in mycobacteria is extremely stable yet experiments have shown that this is 
not due to any form of covalent linkage (48). It is hypothesized that hydrogen bonds 
and π-π bond interactions between naphthoquinone and the aromatic amino acids 
(phenylalanine, tryptophan, and tyrosine) are the major stabilizers (49). 
Mechanism of resistance. The DNA-dependent RNA polymerase (the target for 
rifampicin binding) is encoded by the rpoβ gene as shown in figure 5 (37, 48).   
 
Figure 5. Mutations in codons 507 - 533 of the rpoB gene (37) 
Wild type rpoβ 
 
 
 
 
Mutations 
 
Entering DNA 
 
   13 
Spontaneous mutations (deletions/substitutions/insertions), occurring in the 81-bp hot-
spot region of the rpoβ gene result into replacement of the aromatic with non-aromatic 
amino acids in the target RNA polymerase enzyme (figure 5). This results into poor 
bonding between rifampicin and the RNA polymerase (37, 48), and activity of the 
enzyme (transcription) is preserved, thus explaining resistance to rifampicin in bacteria. 
 
1.4 DEVELOPMENT OF DRUG RESISTANT TUBERCULOSIS  
In the 1940’s, when mono therapy with PAS or S was used as treatment for TB, high 
rates of treatment failures were observed, but was controlled by combining two or more 
drugs (50). Molecular genetic studies dating to the 1970s showed that resistance to anti-
TB drugs resulted from naturally occurring mutations in the genome of M. tuberculosis 
(51). Subsequent studies demonstrated that within a population of M. tuberculosis there 
are mutants that arise due to spontaneous point or deletion mutations (52). Mutations in 
genes encoding drug targets or drug activating enzymes are responsible for resistance, 
and such mutations have been found for all first-line drugs and some second line drugs 
(37).  
 
For a given drug, resistant mutants occur approximately once in every 107 to 1010 cells 
(53-54). Therapy with one drug therefore results into rapid selection for the drug-
resistant mutants, which will dominate the lesions in the patient. The occurrence of one 
mutant strain with resistance to two drugs simultaneously, requires a theoretical 
population of 1016 mycobacterial cells. Thus, combining two or more anti-TB drugs 
reduces effectively, the risk of selecting for resistant mutants in a predominantly 
susceptible population of M. tuberculosis. Indeed by combining PAS and S in the 
1940s, the treatment failure rate was reduced to 9% (55). Since then, combination 
chemotherapy remained the cornerstone for TB treatment. Multi drug resistant and 
extensively drug resistant TB strains arise by sequential accumulation of resistant 
mutants to individual drugs until the strain is resistant to drugs that define these forms 
of resistance. 
 
1.5 TB DRUG SUSCEPTIBILITY TESTING 
1.5.1 General considerations 
Determination of resistance to a given drug is performed as an in-vitro assay in the 
laboratory, a process called drug susceptibility testing (DST). Where resources are 
limited, the WHO recommends a hierarchy of DST that should include at least R and H 
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- the two most efficacious drugs that define MDR-TB (22). For more than 40 years, 
DST  in the developing countries has relied on conventional indirect susceptibility 
methods on Lowenstein-Jensen (LJ) solid medium (56).  Indirect testing involves 
primary isolation of pure colonies of Mycobacterium tuberculosis, which are then used as 
inoculum for DST. In contrast, direct DST involves inoculation of processed smear positive 
samples rather than pure MTB colonies. Results of direct testing are much more rapid and 
help to triage MDR from non-MDR-TB patients promptly.  
 
1.5.2 Conventional Susceptibility Tests 
Three conventional techniques - the proportion method, the absolute concentration and 
resistance ratio have been standardized, and are widely used in the developing countries 
(57).  
Proportion method. With this method, an equal quantity of a standardized inoculum of 
M. tuberculosis is seeded on a drug-free and drug-containing medium. The drug free 
medium is seeded with an inoculum that is 100 times diluted compared with that 
seeded on the drug-containing medium. Distinct, countable colony-forming units 
(CFU) should be present on the drug-free medium.  On the drug-containing medium, 
only pre-existing resistant mutants are expected to grow.  Although the proportion of 
pre-existing mutants based on a mutation rate of 1 in 107-10 would be much lower, for 
ease of interpretation, it is theoretically assumed to be 1%, and this has been 
determined to predict therapeutic outcome (58).  Assuming that 1% of the inoculum on 
the drug medium are resistant mutants, only these mutants will grow, and by dividing 
the number of CFU on drug medium by those on drug free medium it is possible to 
deduce that the isolate is susceptible (≤ 1%) or resistant (>1%). Thus to interpret as 
susceptible, the number of CFU on the drug medium must not exceed those on drug 
free medium. This is the principle underlying the proportional method of DST in MTB 
(56, 58).  
 
The proportion method can be performed on LJ or Middlebrook agar medium (59). The 
LJ medium is recommended by the WHO and the IUATLD for developing countries as 
it is cheap, easy to read, has low contamination rates and DST results are highly 
reproducible (60).  With the PM, estimation of the inoculum size from the colony-
forming units (CFU) counts is easy. However, a single CFU could arise from a clump 
of bacilli rather than from an individual cell, resulting in an inaccurate calculation of 
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the proportion of resistant mutants and thus false results. The LJPM is the DST method 
commonly used in Uganda and in many other developing countries.   
 
Critical concentrations of drugs: The critical concentration (CC) is defined as the 
concentration that Inhibits in-vitro growth of most MTB  cells within the population of 
wild type strains without appreciably affecting the growth of pre-existing resistant 
mutants (58). Table 2 shows the CC for selected commonly tested anti-TB drugs for the 
different tests.  If resistant mutants exceed 1%, the CC may not inhibit growth, and this 
predicts therapeutic failure.  
 
Table 2.  Critical concentration of commonly tested anti-TB drugs 
Critical concentration, µg/ml 
Middlebrook agar, 
 
 
Drug 
Indirect 
LJPM 7H10 7H11 
BACTEC 
460 
MGIT 960 
First line drugs      
Isoniazid 0.2 0.2 0.2 0.1 0.1 
Rampin 40.0 1.0 1.0 2.0 1.0 
Ethambutol 2. 0 5.0 7.5 2.5 5.0 
Pyrazinamide - - - 100.0 100.0 
Injectable Anti-TB drugs      
Streptomycin 4.0 2.0 2.0 2.0 1.0 
Kanamycin 30.0 5.0 6.0 4.0 - 
Amikacin - - - 1.0 1.0 
Capreomycin 40.0 10.0 10.0 1.25 2.5 
Fluoroquinolones      
Ciprofloxacin 2.0 2.0 2.0 2.0 1.0 
Ofloxacin 2.0 2.0 2.0 2.0 2.0 
Levofloxacin - 2.0 - - 2.0 
Moxifloxacin - - - 0.5 0.25 
Gatifloxacin - 1.0 - - - 
Oral Bacteriostatic second-
line Anti-TB agents 
     
Ethionamide 40.0 5.0 10.0 2.5 5.0 
Prothionamide 40.0 - - 1.25 2.5 
Cycloserine 40 .0 - - - - 
PAS 1.0 2.0 8.0 2.0 - 
LJPM = Loweinstein-Jensen proportion method; MIC = Minimum Inhibitory concentration; MGIT = Mycobacterium 
Growth Indicator Tube; LJ = Lowenstein-Jensen; PAS = p-amino salicylic acid. 
Source: World Health Organization (61) 
  
The absolute concentration method.  An inoculum of M. tuberculosis is added to LJ or 
7H10/7H11 agar containing several sequential dilutions of each drug. Resistance is 
indicated by the lowest concentration of the drug that Inhibits growth, i.e. fewer than 20 
colonies by the end of 4 weeks (62).  
 
The resistance ratio method. The resistance ratio (RR) is the ratio of the minimum 
Inhibitory concentration (MIC) for the patients’ strain to the MIC of the drug-
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susceptible reference strain, H37Rv, both tested in the same experiment (63). After 4 
weeks of incubation, growth on any slope is defined as the presence of 20 or more 
colonies, and MIC is defined as the lowest drug concentration where the number of 
colonies is less than 20. A resistance ratio of 2 or less indicates sensitive strain, and a 
resistance ratio of 8 or more indicates resistant strains (58). The RR method is the most 
expensive of the three conventional methods (63).   
 
Conventional tests have been time tested to offer very reproducible DST results and 
have been considered as the gold standard tests for TB susceptibility testing. However, 
when performed on solid medium - typical of RLSs, the DST process is very slow (2-3 
months), necessitating the need for more rapid assays.  
 
1.5.3 New Rapid Susceptibility Tests  
At the beginning of this research programme in September 2006, the new rapid 
susceptibility tests in the literature included Solid media culture-based techniques 
such as Nitrate Reductase Assay (NRA) (64), E test (AB Bio Disk Solna, Sweden) (65-
66), and Phage-based susceptibility tests (Biotec Laboratories Ltd., Ipswich, UK, (67-
68); In-house liquid media culture-based tests such as the  microscopic observation 
drug susceptibility (MODS) assay  (69),  Alamar blue (70), the MTT test (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (71), and resazurin assays (72); 
commercial liquid media culture-based tests such as the BACTEC 460 radiometric 
system (Becton Dickinson, Sparks, Maryland), Mycobacterium Growth Indicator Tube 
- MGIT (Becton Dickinson, Sparks, Maryland), and MB BacT/Alert system 
(bioMe´rieux, Marcy l’Etoile, France) (73-74); and Molecular tests (Line Probe 
Assays) such as the INNO-LiPA Rif. TB Assay (Innogenetics, Ghent, Belgium) (75)  
and the Genotype® MTBDR and its newer version - the Genotype® MTBDRplus (Hain 
Life sciences, Nehren, Germany) (76).  
 
Solid Media Culture-Based Tests 
 
Nitrate reductase assay (NRA). Mycobacteria tuberculosis has nitro- reductase 
enzymes that catabolically reduce nitrate (NO3) to nitrite (NO2), in the reaction 
pathway: 
KNO3 + 2e- + 2H                 NO2 + 2H2O 
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In 1879, Griess, a German chemist working at the University of Marburg, described the 
diazotization reaction, which now forms the basis for the Griess test for the detection of 
nitrite (77). By incorporating 1mg/mL potassium nitrate (KNO3) in the medium, the 
reduction of nitrate to nitrite can be detected using the Griess reagent. When Griess 
reagent is added on the 7th-21st day of incubation, the nitrite in the medium causes a 
pink-purplish color. In the presence of R or H at the critical concentrations, the 
appearance of a pink-purple colour represents resistance to the drug (64).  Susceptible 
strains do not grow, as they are inhibited by the antibiotic thus producing a non-
coloured reaction. As the NRA uses the detection of nitrate reduction as an indicator of 
growth, DST results can be obtained faster than by waiting for visual detection of 
colonies.  
 
Progress had been made in the use of the NRA for indirect DST in M. tuberculosis 
showing sensitivity and specificity of 92-100% (78). The NRA test is technically easy 
to set and read, and gives a clear cut answer on susceptibility. When NRA is used for 
indirect DST, the bio safety and cost is almost similar to the LJPM since it needs a 
minor modification to perform the test. However, data on the performance of the NRA 
in RLSs in Africa was limited (78). It was therefore essential to further evaluate the 
NRA test procedures before it gets considered for routine MDR-TB diagnosis in RLS.  
 
E test susceptibility testing. This method uses plastic strips that contain exponential 
gradients of antibiotics for susceptibility testing of mycobacteria (AB BIODISK, Solna, 
Sweden).  The antibiotic diffuses into the medium and thereby inhibiting growth of 
susceptible strains. The minimum inhibitory concentration (MIC) is read and the isolate 
interpreted as resistant or susceptible. Initial studies of the E test showed high accuracy 
estimates of close to 100% when compared with the conventional agar proportion and 
BACTEC radiometric tests (65-66). However, it is now known that the diffused 
antibiotics degrade fast amidst the slowly growing mycobacteria resulting in a blurred 
cut off point for MIC reading. The other disadvantage of the E test is the need for a 
heavy inoculum i.e. #3 MarcFarland (MF) equivalent, which may not be achievable 
with direct DST on sputum sediments, but which also poses a major risk of aerosol 
generation and inhalation by the staff in the safety level 2 laboratories of developing 
countries. The E test antibiotic strips are also very expensive (up to USD 30 per strip), 
which may not be affordable in RLSs. With these issues, the E test was not found to be 
suitable for further evaluation in this research programme.   
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Phage-based susceptibility tests. Phage assays rely on the ability of live and thus 
resistant M. tuberculosis pre-incubated with the test drug to support the growth of an 
infecting mycobacteriophage - a virus that infects mycobacteria (68, 79). Both the 
commercially available FastPlaque TB assay and the in-house versions have been 
mainly studied for the detection of  rifampicin resistance of either M. tuberculosis 
isolates or directly on clinical specimens with good results and rapid time to results of 
2-3 days (67-68). An evaluation of this assay in Uganda also showed high sensitivity 
and specificity (80). However, the phage assay can be technically complex, labour-
intensive, and can have high failure rates with inability to have interpretable results 
(Joloba M personal communication). This test was excluded from further evaluation. 
 
In-House Liquid Media Culture-Based Tests  
 
Microscopic-observation drug-susceptibility (MODS) assay. The MODS assay is a 
broth-based technique for the detection of tuberculosis and multidrug-resistant 
tuberculosis, indirectly or directly from sputum. The test relies on three principles (69): 
first, Mycobacterium tuberculosis grows faster in liquid medium than in solid medium; 
second, characteristic cord formation occurs and these cords can be visualized 
microscopically in liquid medium at an early stage; and third,  incorporation of drugs 
permits rapid and direct drug-susceptibility testing concomitantly with the detection of 
bacterial growth. Resistant strains are detected due to the ability of M. tuberculosis to 
grow with characteristic cord-like structures detected with an inverted microscope. 
Visualization of cord-like structures in liquid medium containing the tested drug 
indicates resistance.  Recently, the protocol for the MODS assay has been updated to  
include a well with Para-Nitrobenzoic Acid (PNB) to help identify MTB from atypical 
mycobacteria. PNB inhibits growth of MTB complex but not atypical mycobacteria 
(81). 
Studies on MODS have shown sensitivities and specificities ranging from 86-100% for 
rifampicin and isoniazid resistance (69, 82). The MODS assay requires minimal 
training, is easy to set and results are rapid (7-14 days). However, microscopic 
observation of the cords may be subjective. Being a liquid culture-based test performed 
on tissue culture plates, concerns have been raised over the bio safety of staff working 
with this test.  However, the main bio safety concern is at the point of sputum 
processing and inoculation after which the plate is supposedly sealed and never re-
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opened even at microscopic examination. On basis of rapidity (7-14 days), technical 
ease, and low cost, the MODS assay was thought to be a promising DST method for 
poor countries, and was therefore listed for further analysis of the accuracy and 
operational issues in Uganda.  
 
Alamar blue, Resazurin and MTT assays. These tests are referred to as colorimetric 
assays since they involve oxidation-reduction reactions with a colour change (83). They 
all use liquid medium on 96-well micro titre plates although tube assays have been 
reported (84). Supplemented 7H9 broth containing the test drug is inoculated with 
mycobacteria and incubated for 7 days at 37oC. After addition of Alamar blue or 
resazurin reagents to wells and if there is bacterial growth, the blue oxidized reagent is 
reduced to a pink dye visible with the naked eye or with a colorimeter.  A change of 
colour from blue to pink in a drug-containing well indicates presence of growing 
resistant M. tuberculosis (85). For the MTT assay, detection of resistance is based on 
the ability of mitochondrial dehdrogenase enzymes from viable mycobacterial cells to 
cleave the tetrazolium rings of the pale yellow MTT, resulting in formation of violet-
purple or dark blue formazan, visible with a naked eye or with a colorimeter (72). After 
the 7 days incubation the yellow MTT is added to the wells, and the plate incubated for 
24 hours to allow the MTT to precipitate in the cytoplasm. A lysing buffer is then 
added to the wells to lyse the bacterial cell and release the MTT into the medium. 
Development of a strong violet-purple colour in the drug-containing well indicates 
presence of resistant mycobacterial strains (72).   
 
Each of these colorimetric methods has been assessed in previous studies with reported 
sensitivity and specificity of 94-100%, and the results obtained within 10 days (83). 
These tests use micro titre plates with around 10 samples per plate, thus high 
throughput, which would be good for TB high-burden settings. However, after 7 days 
of incubation, the Alamar blue and resazurin plates are opened once while the MTT 
plate must be opened twice to add the detection reagents. This is not only cumbersome 
but also carries a serious bio safety risk to the laboratory personnel. On basis of high 
throughput these tests were listed for further analysis to asses their performance in 
Uganda even though they but may not be optimal for safety level-2 TB laboratories.   
 
 20 
 
Commercial Liquid Media Culture-Based Tests  
 
BACTEC 460. The BACTEC 460 (Becton Dickinson, Sparks, Maryland) relies on 
radiometric detection of 14CO2 as an indicator of bacterial growth.  The Bactec vials 
contain Middlebrook 7H12 medium and fatty acid substrates labeled with 14C.  
Growing mycobacteria release 14CO2 as a metabolic end product. The gas is removed, 
analyzed and the amount of radioactive 14C is expressed as a numerical value called the 
Growth Index (GI). When the GI value in the control vial reaches 30 interpretation of 
drug tube begins on the next day as follows. Susceptible: Change in GI in the control 
vial > GI in drug vial; Resistant: Change in GI in control vial < GI in drug vial and 
Border line: GI in control vial = GI in drug vial. This test is highly sensitive and 
specific but it uses radioactive carbon whose half life is 5,000 years, which makes it 
difficult and expensive to dispose. Due to these issues, the BACTEC 460 is being 
phased out and has been replaced by non-radiometric systems such as the 
Mycobacterial Growth Indicator Tube and the MB/BactAlert system. The BACTEC 
460 test was therefore not evaluated further in this study. 
 
Mycobacterial Growth Indicator Tube. The Mycobacterial Growth Indicator Tube 
(MGIT; Becton Dickinson, Sparks, Maryland, USA) is based on fluorescence detection 
of mycobacterial growth in a tube containing a modified Middlebrook 7H9 medium 
together with fluorescence quenching-based oxygen sensor (a ruthenium pentahydrate 
substance embedded in silicone rubber) at the bottom of the tube (86-87). As the 
bacteria grow and consume oxygen, the indicator fluoresces under ultraviolet light, and 
growth in a tube with the test drug indicates resistance (86). The MGIT system, 
introduced around 15 years ago, in its manual and now automated versions, is part of 
the new-generation of rapid tests for detection of drug resistant TB.  Studies of both the 
manual and automated MGIT 960 system have shown very high correlation with 
conventional DST methods for rapid detection of resistance to the first and second-line 
anti-TB drugs (88-90).   
 
The automated MGIT 960 system has the advantage of high throughput (>900 samples 
can be tested on one instrument at ago), it is rapid (4-13days), and very easy to interpret 
results. All these aspects would be suitable for the TB high-burden settings. However, 
the test has been studied only as an indirect assay mainly in the developed countries. 
   21 
Thus, there is limited data on the technical performance of the test in RLS, and on how 
the operational issues such as cost, contamination rates, and power failures would 
impact on the DST results in the low income settings. In this study, the automated 
MGIT 960 system was evaluated as both a direct and an indirect DST assay at 
Kampala. 
 
The BacT/ALERT ® 3D System. The BacT/ALERT ® 3D System (bioMe´rieux, Marcy 
Etoile France) is a liquid based automated assay performed in a tube with a liquid 
emulsion sensor. Growing bacteria produce CO2, which reacts with the sensor, 
resulting is a colour change from gray to a lighter colour, detected colorimetrically as 
growth. Growth in a drug tube indicates resistance.  The BacT/ALERT ® 3D System is 
slightly slow compared with the MGIT 960. This test was thus excluded from further 
analysis. 
 
Molecular Assays  
Molecular methods for MDR-TB detect the common mutations conferring resistance to 
R and H, rather than the resistance phenotype. The commercially available line probe 
assays involve DNA extraction, polymerase chain reaction (PCR), and solid phase 
reverse hybridization of amplified DNA to probes covering the core region of the target 
gene, immobilized on a nitrocellulose strip. These tests can be applied on MTB isolates 
or on sputum smear positive sputum (91-92).  
 
The INNO-LiPA Rif TB Assay (Innogenetics, Ghent, Belgium) detects the common 
mutations in only the rpoB gene for rifampicin resistance (92).  Evaluation studies of 
the INNO-LiPA Rif. TB Assay showed high sensitivity and specificity (75). Rifampicin 
resistance predicts MDR-TB in over 90% of cases, and may be sufficient for MDR 
diagnosis. However, isoniazid testing as well may be helpful in the design of second 
line drug regimens for MDR-TB patients. The GenoType® MTBDR assay (Hain 
Lifesciences, Nehren, Germany) simultaneously detects the common mutations in the 
rpoB and katG gene (93). The GenoType® MTBDRplus, a newer version of the 
genotype MTBDR detects more of the common mutations in the rpoB and katG genes, 
and also mutations in the inhA promoter region, making it the most sensitive line probe 
assay for detection of resistance (94). Evaluation studies of these assays have reported 
sensitivity and specificity of 98-100% for rifampicin, and of 70-100% for isoniazid, 
with results in 1-3 days (95).   
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Most of these studies were performed in developed countries and there was limited data 
on the performance of the tests in developing countries (95).  A major limitation of 
these assays in developing countries could be the expertise in molecular biology 
required to perform them correctly, the unidirectional work flow laboratory 
infrastructure and the cost of molecular assays. However, a study on the INNO-LiPA 
Rif. TB assay in Rwanda demonstrated that the required skills could be learnt in a 
matter of weeks (96). Additionally, many of the developing countries now have 
facilities for basic molecular biology as used in monitoring viral load in HIV treatment.  
Thus, based on high sensitivity and specificity, rapidity, and potential ease of use, we 
considered the GenoType® MTBDR assay and GenoType® MTBDRplus for further 
assessment in Uganda.  
 
To conclude this section, apart from the intrinsic properties, the performance of 
diagnostic tests also depend on the prior probability of disease in the study population, 
and the design of the study (97). The design of some of the studies cited above were 
typical of in stage 1 or 2 of test development, and were mostly conducted in the 
resource-rich settings (98). Some of the studies were done on very diverse or 
intentionally biased study populations, casting uncertainty on the wider applicability of 
the results, particularly in the RLSs (78, 83, 95). Furthermore, recent MDR-TB 
diagnostic research has focused on direct susceptibility testing. However, data on the 
listed tests when used as direct assays was very limited.  The WHO in July 2010 
recommended the use of colorimetric tests, MODS and the NRA for TB susceptibility 
testing in RLSs, but the available data to support the recommendation of for example 
the NRA in RLSs was admittedly limited (99). In this thesis we provide more recent 
data and experience with these assays in a typical RLS.  
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2 ABOUT THIS THESIS  
 
This thesis is based on a 4-year research program that begun in September 2006. The 
overall goal of the research program was to find and recommend highly accurate, 
affordable and easy to use test(s) for diagnosis of MDR-TB in RLSs. We compared several 
rapid tests for detection of drug resistant tuberculosis on sensitivity, specificity, time to 
results, contamination rates, cost, bio safety and reproducibility in the perspective of 
resource-limited settings.  
 
2.1 CONCEPTUAL FRAMEWORK   
In the RLSs, there is limited capacity to perform TB DST even at national reference 
laboratories. DST with the LJPM, which sometimes is available in these settings, is 
considered to be cheap and the results accurate but come too late to be useful in patient 
care. As a result, TB treatment is based on standard WHO drug regimens. For the new TB 
cases oral drugs are given, and the two-months intensive phase involves use of R, H, Z and 
E, followed by a 6-months continuation phase with H and E  (i.e. 2RHZE/6HE). For the re-
treatment patients, the intensive phase goes on for 3 months.  For the first two-months 
injectable S plus oral R, H, Z, and E are used; followed by one month of H, E, R, Z; and 
then five months of H, E, R (i.e. 2SRHZE/1RHZE/5RHE).  
 
In case of MDR-TB particularly among the re-treatment cases, the standard regimen may 
not be effective since only streptomycin is added to a failing regimen. Patients may thus 
deteriorate and remain infectious to many new contacts, which may lead to MDR-TB 
outbreaks (17-18, 100).  In case of susceptible TB, which constitute 80-85% of the re-
treatment cases in sub-Saharan Africa, the simpler oral regimen used in the new TB cases 
could as well be effective. Thus, using injectable streptomycin may represent unnecessary 
treatment and wastage of resources; moreover the drug is more toxic than the simpler oral 
regimens. Therefore, rapid tests to screen for MDR-TB would help Physicians to triage 
patients early for the appropriate treatment. This would improve the patients’ condition, 
curtail the spread of MDR-TB and optimize drug usage (see figure 6).  
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2.2 SPECIFIC OBJECTIVES 
1. To conduct a meta-analysis comparing the sensitivity, specificity and time to 
results of rapid MDR-TB tests.  
 
2. To compare the sensitivity, specificity and time to results of rapid indirect tests 
for MDR-TB against the LJPM.  
 
3. To compare the proportion of interpretable susceptibility results, results 
obtained at initial testing, contamination rates, sensitivity and specificity, time 
to results, cost of testing, and reproducibility of direct assays for MDR-TB at 
Kampala, Uganda. 
 
4. To investigate the clustering rate and the predominant genotypic lineages of 
MDR-TB strains spreading in Kampala, Uganda.  
Figure 6. Conceptual framework 
Very long waiting time (≥60-90days) 
• If MDR-TB,  
¾ No response to routine drug regimens 
¾ Patient’s condition deteriorates  
¾ Continued spread to family, health workers & 
community (MDR-TB amplified)  
¾ MDR-TB outbreaks in hospitals, prisons etc  
• If Non-MDR,  
¾ Injectable streptomycin wasted 
¾ Simpler oral regimen could be adequate  
 
MDR-TB suspect  
Conventional DST on LJ 
medium 
• Results in 60-90 days 
DST with new rapid tests 
Results in 2-14 days 
 
Short waiting time (2-14 days) 
• If MDR-TB,  
9 Initiate MDR-TB treatment early 
9 Patient condition improves  
9 Curtail spread of MDR strains  
9 MDR-TB controlled  
9 Outbreaks mitigated 
 
• If Non-MDR,  
9 Stop streptomycin 
9 Continue with oral simpler drug regimen  
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3 OVERVIEW OF THESIS PAPERS 
 
This thesis is based on five papers. In paper I, a meta-analysis of direct rapid 
susceptibility tests was conducted. In paper II, the rapid tests were compared as indirect 
susceptibility assays in Uganda. In paper III, the tests were compared as direct assays in 
Uganda. In paper IV, one molecular test was studied for technical performance and 
reproducibility in two laboratories in Uganda, while in paper V, we studied the 
clustering rate and predominant strains of MDR-TB spreading in Kampala.  
 
3.1 STATISTICS AND DATA ANALYSIS  
In paper I (meta-analysis), The Meta-Disc® software (101) was used to analyse the 
reports and tests for sensitivity, specificity, and area under the summary receiver 
operating characteristic (sROC) curves. Heterogeneity in accuracy estimates was 
tested with the Spearman correlation coefficient and Chi-square.  
In papers II and III,   the data was entered in Microsoft Excel 2007 (Microsoft 
corporation, Redmond, WA, USA), and then imported into SPSS 11.0 for Windows 
(Statistical Package for the Social Sciences, Chicago, IL, USA) where two-by-two 
tables on true-resistant (TR), false resistant (FR), false-susceptible (FS), true 
susceptible (TS) and kappa agreements were generated. A kappa agreement of greater 
than 0.75 was considered excellent agreement beyond chance between the new rapid 
test and the reference test. Sensiivity, i.e., the proportion of drug-resistant TB strains 
correctly identified by the new rapid test (true-positive), specificity, i.e., the 
proportion of susceptible isolates correctly identified (true-negative) and the 95% 
confidence intervals were computed with the Meta-Disc® software. Time to results 
and cost estimates were computed in Microsoft Excel 2007 (Microsoft, Redmond, 
WA, USA).  
In paper IV, statistical tests were performed using Intercooled STATA 8.0 software 
(Statacorp LP, College Station, TX, USA) and Microsoft Excel 7.0 as referenced 
above. Results were considered significant at p value of < 0.05.  
In paper V, spoligotypes were entered into an online spoligotyping database of the 
Pasteur Institute of Guadeloupe (http://www.pasteur-guadeloupe.fr/tb/bd_myco.html ), 
which assigned them octal numbers and lineages.  
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3.2 PAPER I 
 
META-ANALYSIS COMPARING THE SENSITIVITY, SPECIFICITY AND 
TIME TO RESULTS OF RAPID MDR-TB TESTS  
 
The main aim of this phase of the research program was to find out which rapid tests 
were available, and which ones had prospects for applicability in RLSs. We reviewed 
literature in journals, textbooks and electronic resources, and based on high accuracies 
as reported by authors, a priority list of tests for further study was prepared. The 
priority tests included the nitrate reductase assay (NRA), E test, microscopic 
observation drug susceptibility (MODS), alamar blue, MTT assay (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), manual and automated 
mycobacterium growth indicator tube (MGIT:  Becton Dickinson, Sparks, Maryland), 
Genotype MTBDR® and Genotype® MTBDRplus (Hain life sciences, Nehren, 
Germany)  
 
We then conducted meta-analysis of the rapid assay reports on direct susceptibility 
testing for MDR-TB.  In the meta-analysis we compared the sensitivity, specificity and 
time to results (TTR) of four direct drug susceptibility testing assays with the 
conventional indirect testing for detection of resistance to R and H in M. tuberculosis. 
The four direct tests included two in-house phenotypic assays – Nitrate Reductase 
Assay (NRA) and Microscopic Observation Drug Susceptibility (MODS), and two 
commercially available tests – Genotype® MTBDR and Genotype® MTBDRplus 
(Hain Life Sciences, Nehren, Germany). The MetaDisc software (101) was used to 
compute the sensitivity, specificity, and area under the summary Receiver Operator 
Characteristic Curves (sROC).  
 
Eighteen direct DST reports were analysed: NRA – 4, MODS- 6, Genotype 
MTBDR® – 3 and Genotype® MTBDRplus – 5. The pooled sensitivity and 
specificity for detection of resistance to rifampicin were 99% and 100% with NRA, 
96% and 96% with MODS, 99% and 98% with Genotype® MTBDR, and 99% and 
99% with the new Genotype® MTBDRplus, respectively. For isoniazid it was 94% 
and 100% for NRA, 92% and 96% for MODS, 71% and 100% for Genotype® 
MTBDR, and 96% and 100% with the Genotype® MTBDRplus, respectively. The 
area under the summary receiver operating characteristic (sROC) curves was in 
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ranges of 0.98 to 1.00 for each of the four tests. Molecular tests were completed in 1 – 
2 days and the phenotypic assays were also much more rapid than conventional 
testing. Results of the meta-analysis on direct testing were published in paper 1 (102) 
 
Based on the high test accuracies and performance characteristics revealed during the 
literature review and meta-analysis, seven test methods (NRA, MODS, Genotype® 
MTBDRplus, MGIT 960, Alamar blue, Resazurin and MTT) were selected for further 
evaluation as indirect susceptibility tests at Kampala, Uganda.   
 
3.3 PAPER II 
SENSITIVITY, SPECIFICITY AND TIME TO RESULTS OF SEVEN RAPID 
TESTS FOR MDR-TB STUDIED AS INDIRECT ASSAYS AT KAMPALA  
In research on diagnostic tests, before any test is recommended for routine use in a new 
setting, it is critical to study the performance of the test in that specific setting (98).  
The current phase of the research program was undertaken at the NTRL Kampala, 
Uganda - a typical resource-limited setting which is the target of the tests studied. 
Thirty-one well-characterized strains of M. tuberculosis were tested for susceptibility to 
R and H with seven rapid assays (NRA, MODS, MGIT 960, Genotype® MTBDRplus, 
Alamar blue, MTT and resazurin), which were compared head-to-head for sensitivity, 
specificity and time to results, against the LJPM as reference test.  
 
The NRA correctly identified all the resistant strains with 100% sensitivity and 
specificity. The MGIT 960 detected all MDR strains but missed one R-mono resistant 
strain. The Genotype® MTBDRplus detected all R-resistant strains and the sensitivity 
for detection of H resistance was 88%. Sensitivity and specificity ranged from 86% to 
100% with MODS, and from 57% to 100% with Alamar blue, MTT and resazurin 
assays for both drugs. Test results were obtained within 2–14 days.  
 
Additionally, major cost areas, bio safety needs and technical ease were qualitatively 
assessed with regard to the existing TB laboratory infrastructure at the NTRL in 
Kampala. The NRA did not require additional instrumentation, while the MODS 
required an inverted microscope. The Genotype® MTBDRplus required laboratory re-
designing and several instruments for molecular testing but their estimated total cost 
was not as expensive as for the MGIT 960 instrument (table 3). 
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Table 3.  Qualitative assessment of major cost areas, bio safety needs and technical 
ease of new tests compared with the LJPM 
 
Cost (H & R testing) 
 
Bio safety hood needed  
Indirect DST 
Major investment / 
Infrastructure   
cost areas 
Running Costs 
(Reagents & 
supplies) 
DST 
inoculation 
DST 
reading 
Technical ease 
assessment 
LJPM 
• BSL- 2 laboratory 
(Room with air lock 
door and a Bio 
safety cabinet) 
• Centrifuge  
• Incubator  
• Autoclave 
• Fridge and Freezer 
• LJ reagents Yes No 
Cumbersome 
to set but easy 
to read.  Slow  
NRA 
• As for LJPM • As for LJ  
plus 
• KNO3  
• Griess 
reagent  
Yes       Yes 
Easy to set 
and simple to 
read 
MGIT 960 
• BSL-3 laboratory 
(Room with 
negative air flow 
and Bio safety 
cabinet) 
• MGIT instrument 
• Other instruments as 
for LJPM 
• MGIT 
Medium 
• Supplements 
• Other 
supplies 
Yes No 
Cumbersome 
to set but easy 
to read 
Genotype® 
MTBDRplus  
• Laboratory re-
design 
• BSL-2 laboratory 
• UV work station 
• Microcentrifuge 
• Sonicator  
• Thermocycler 
• Twincubator® 
• Other instruments 
as for LJPM 
• Kits  
expensive 
but may be 
cost-
effective 
Yes No 
Training  in 
PCR & 
Hybridization 
Many steps  
MODS 
• BSL-2 laboratory   
• Inverted microscope 
• Other instruments as 
for LJPM 
• Tissue 
culture 
plates  
• 7H9 broth  
• OADC and 
PANTA 
Yes No 
Easy to set 
but reading 
may be 
subjective  
Alamar blue 
MTT 
Resazurin 
• BSL- 3 laboratory  
• Other instruments 
as for LJPM 
• Alamar blue 
reagent 
• Micro titre 
plates 
• Tape seal 
Yes       Yes 
Cumbersome 
to set and 
read 
 
In the study setting, the NRA was the most accurate assay for indirect detection of 
MDR-TB, followed by the MGIT 960, Genotype® MTBDRplus and MODS. Time to 
results was significantly shorter compared to conventional testing.  These results were 
published in paper II (103).  
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Indirect susceptibility testing requires prior isolation of M. tuberculosis in pure 
colonies, which may take 21-60 days on solid medium. Additionally, even after 
isolation of the MTB in pure colonies, RLSs face unique challenges such as staff 
inadequacy, suboptimal work habits, stock outs and lost/misplaced culture tubes, which 
all tend to delay inoculation, reading and reporting of the susceptibility result. 
Therefore, the overall time from the date of sample receipt in the laboratory to 
obtaining a valid DST result is markedly prolonged – in most cases to at least 90 days 
at the NTRL Kampala, Uganda. Some of these issues could be minimized by 
performing direct DST. Therefore, based on high test accuracy revealed in the above 
study and also in the meta-analysis, two in-house assays (NRA and MODS) and two 
commercially available tests (Genotype® MTBDRplus and MGIT 960) were further 
evaluated as direct DST assays at Kampala, Uganda.   
 
 
3.4 PAPER III  
PROPORTION OF INTERPRETABLE SUSCEPTIBILITY RESULTS, 
RESULTS OBTAINED AT INITIAL TESTING, CONTAMINATION RATES, 
SENSITIVITY, SPECIFICITY, TIME TO RESULTS AND COST PER 
SAMPLE OF DIRECT ASSAYS FOR MDR-TB AT KAMPALA, UGANDA 
Direct susceptibility testing in which decontaminated respiratory samples are 
inoculated in drug-free and drug-containing medium or amplified for detection of 
MDR-TB straight away eliminates the time needed for prior isolation of MTB and 
minimizes the related obstacles mentioned above. Furthermore, preliminary evidence 
from the meta-analysis indicated that direct testing for MDR-TB with the NRA, MODS 
and Genotype® MTBDRplus was highly sensitive and specific, and far more rapid than 
the conventional indirect DST (102). However, some of direct DST reports meta-analysed 
had insufficient study designs, that may limit generalization of the findings (102).  
 
In this part of the research program, the NRA and MODS were compared on proportion 
of interpretable susceptibility results, results obtained at initial testing, contamination 
rates, sensitivity, specificity, time to results, and cost of testing per sample as direct 
MDR-TB assays at the NTRL Kampala. The performance of the direct MGIT 960 was 
also assessed. Retreatment TB patients were consecutively recruited at the TB clinic of 
Mulago National Referral Hospital. Ziehl-Neelsen smear positive sputum was collected 
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from 245 patients and was processed at the NTRL. Sediments were tested for 
susceptibility to R and H with the direct NRA, MODS and MGIT 960 at the NTRL, 
while a portion of it was tested with the direct Genotype® MTBDRplus at the 
department of Medical Microbiology Makerere University College of Health Sciences 
and at the FIND diagnostics laboratory at Kampala, Uganda. Methodological details for 
the direct NRA and MODS assays are shown in paper III (Manuscript), and for the 
molecular assays in paper IV(104).   
 
Results 
Interpretable results. Interpretable results were obtained in 225 (92%), 229(93%), 211 
(86%) and 226 (92%) of samples with the direct NRA, MODS, MGIT 960 and indirect 
LJPM, respectively.  
 
Interpretable results obtained at initial testing were 90%, 85% and 80% with the 
direct MODS, NRA and MGIT 960, respectively. Repeat testing was mainly due to 
contamination for NRA, and lack of growth in the control well/tube for MODS and 
MGIT 960. For the samples with no interpretable results - even after repeat testing, 
insufficient growth rather than contamination was the main reason. 
 
Contamination rates. Following initial inoculation, tubes/wells that contaminated were 
22(9%), 12(5%) and 17(7%) of the NRA, MODS and MGIT 960 assays, respectively. 
However, contamination caused total failure to obtain interpretable final results in only 
a few tubes.  
 
Sensitivity and specificity. Samples with interpretable results with both the study test 
and the LJPM were 218, 217 and 203 with the NRA, MODS and MGIT 960, 
respectively. Based on these samples, sensitivity, specificity and kappa agreement for 
MDR-TB diagnosis (R and H resistance) was 95%, 98% and 93% with the NRA, and 
81%, 95% and 75% with the MODS, and 68%, 99% and 75% with the MGIT 960. 
These results are shown in table 4, and more detailed for NRA and MODS in paper III 
(Manuscript). 
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Table 4. Sensitivity, specificity and kappa agreement of the direct NRA, MODS 
and MGIT 960 
 
Drug Direct NRA Direct MODS Direct MGIT 960 
Sensitivity, %  
(95% CI) 
98 
(88-100) 
83  
(68-92) 
68  
(52-81) 
Specificity, %  
(95% CI) 
98 
(91-98) 
94  
(88-97) 
99 
(96-100) 
Rif 
Kappa agreement 0.93 0.74 0.76 
Sensitivity, %  
(95% CI) 
92 
(83-97) 
88  
(77-95) 
87 
(76-94) 
 Specificity, %  
(95% CI) 
96 
(94-99) 
93  
(87-96) 
97  
(93-99) 
INH 
Kappa agreement 0.87 0.79 0.86 
Sensitivity, %  
(95% CI) 
95 
(84-99) 
81  
(70-91) 
68 
(51-81) 
 Specificity, %  
(95% CI) 
98 
(95-100) 
95  
(90-98) 
99 
(96-100) 
Rif 
and 
INH 
Kappa agreement 0.93 0.75 0.75 
 
Time to Results (TTR). The median TTR was 10, 7, 8 and 64 days with the direct 
NRA, MODS, MGIT 960 and indirect LJPM, respectively.  
 
Cost. The cost of laboratory supplies per sample was $3.58, $5.56 and $4.12 with the 
direct NRA, MODS and indirect LJPM, respectively, thus the NRA was the cheaper in 
Uganda’s settings.  
 
To conclude this section, the direct NRA was the most sensitive, specific, and cheapest 
test for MDR-TB in Uganda’s settings. 
 
3.5 PAPER IV  
RAPID SCREENING OF MDR-TB USING MOLECULAR LINE PROBE 
ASSAY IS FEASIBLE IN UGANDA 
  
In this paper, we assessed the performance of a commercial line probe assay (LPA) the 
Genotype® MTBDRplus for direct detection of R and H resistance.  Smear-positive 
sputum specimens from 118 previously treated TB patients were tested.  LPA testing 
was performed at the Department of Medical Microbiology Makerere University.  To 
assess the reproducibility of results, testing was also performed at the FIND diagnostics 
laboratory located within the TB reference laboratory at Kampala, Uganda.  Results 
were compared with the indirect MGIT 960 liquid culture and DST.  
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Overall, 96% of smear-positive specimens gave interpretable results within 1-2 days 
using LPA.  Sensitivity and specificity were 100% and 96% for detection of R 
resistance; 81% and 100% for H resistance; and 92% and 96% for MDR compared with 
MGIT 960 results.  Concordance of susceptibility results between the two laboratories 
was 98%, implying high reproducibility.  We concluded that rapid screening for 
MDR-TB with LPAs is possible in Uganda. Details of the methods and results are 
shown in paper IV (104)  
 
3.6 PAPER V 
CLUSTERING RATE AND PREDOMINANT GENOTYPIC LINEAGES OF 
MDR-TB STRAINS IN KAMPALA, UGANDA  
 
Recent field epidemiological studies suggest a high rate of TB transmission among the 
peri-urban populations of African cities (105-107). Molecular fingerprinting studies 
with restriction fragment length polymorphism (RFLP), variable number of tandem 
DNA repeats (VNTRs) and spoligotyping (108-111) also reveal high clustering rates 
and recent TB transmission in Africa (112-114). These studies have brought to light a 
firm insight into the transmission dynamics of M. tuberculosis in Africa, but they did 
not focus on MDR-TB.  
 
Knowledge of the transmission and predominant genotypes of MDR-TB strains in a 
given geographical region is important for TB control, particularly in understanding 
the transmissibility (115), virulence, immunogenicity and vaccine design (116). 
Whereas the Beijing genotype is highly prevalent and in most cases associated with 
multi drug resistance in Asia, Eastern Europe and New York (117-122), there is no 
parallel data on the MDR-TB strains spreading in Kampala.  
 
In this study we applied the spoligotyping technique to determine the clustering rate 
and predominant genotypic strains of M. tuberculosis causing MDR-TB in Kampala, 
Uganda.   A total of 99 MDR-TB isolates were studied. These isolates were from 
retreatment TB patients attending different health facilities in Kampala. Twenty-four 
strains were isolated consecutively from patients aged 19-56 years (median age 32 
years) at Mulago National Referral Hospital during 2008. These strains had been 
identified as members of the MTB complex using the Capilia TB Neo (TAUNS 
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Corporation, Japan), confirmed MDR with the LJ-PM and kept at -40 oC at the NTRL.  
Seventy-five strains were from TB patients recruited in several research projects at one 
or more of the health facilities in Kampala between 1997 – 2006. The latter strains had 
been identified as members of the MTB complex with PCR for IS6110, tested for 
susceptibility to R and H using the BACTEC 460 or the MGIT 960 and archived at the 
JCRC laboratory.   
 
A commercially available spoligotyping kit (Isogen Bioscience BV, Maarssen, The 
Netherlands) was used to the genotype 99 MDR-TB strains. Spoligotypes were entered 
into the international spoligotyping database of the Pasteur Institute of Guadeloupe 
(http://www.pasteur-guadeloupe.fr/tb/bd_myco.html ) and assigned octal numbers and 
lineages. Clustering was defined by presence of two or more strains with identical 
spoligotypes.  
 
Eighty-two isolates (83%) were part of 10 clusters. The T2 lineage was the largest 
cluster with 26 strains, followed by CAS –Delhi and LAM II ZWE with 13 and 10 
strains, respectively. Seventeen strains did not cluster, twelve of which were total 
orphans while five already were in the database. One Bovis1_BCG lineage was also 
found. We concluded that 83% of the MDR-TB strains in Kampala occur in clusters, 
suggesting a high level of recent MDR-TB transmission. The T2 lineage was the 
largest single MDR-TB cluster, and it was also found earlier to be the most frequent 
genotype responsible for TB in Kampala (123).  Thus there is a local epidemic of the 
T2 genotype causing TB and MDR-TB in Kampala, Uganda.  
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4 CONCLUSIVE REMARKS 
 
The aim of this research program was to compare the technical and operational performance 
of new rapid MDR-TB tests with prospects for applicability in RLSs. Her below a summary 
of the findings is given. 
 
From the meta-analysis of direct tests, the NRA, MODS and Genotype® MTBDRplus were 
highly sensitive and specific.   
 
With indirect DST at Kampala, the NRA, MODS, Genotype® MTBDRplus and 
MGIT 960 tests were highly sensitive, specific and results were obtained much earlier 
than for the LJPM. The NRA did not require any additional instrument with regards 
to the existing infrastructure at the national TB reference laboratory Kampala, 
Uganda, while the MODS assay required an inverted Microscope as the only main 
additional instrument. The Genotype® MTBDRplus required the laboratory to be 
redesigned for the 3 rooms needed for molecular testing and additional instruments 
that were not so expensive. However, the MGIT 960 required a very expensive 
instrument and reagents. On laboratory infrastructure, the NRA, MODS, Genotype® 
MTBDRplus can be performed in a BSL-2 laboratory (room with air lock door and 
bio safety cabinet) – the type of laboratory in Uganda and in many RLSs, but MGIT 
culture and DST requires a BSL-3 laboratory with negative air flow due to high risk 
of aerosol generation.  
 
With direct susceptibility testing, the NRA emerged as the most accurate, cheapest 
and easiest test in the study setting. Technologists in RLSs are familiar with TB 
culture and DST on LJ medium, thus introduction of the direct NRA test appears to 
be easier compared to the other techniques since it is also performed on LJ medium. 
Both the direct NRA and MODS require BSL-2 laboratory for sample processing, 
inoculation and later addition of Griess reagent - in the case of NRA. Since most TB 
laboratories in sub Saharan African countries are of BSL-2 at best, in these settings, 
the highly accurate direct NRA is likely to be the optimal test for rapid screening for 
MDR-TB. Whereas the MODS assay had slightly less sensitivity for MDR-TB 
detection, it can be a very good test for settings with many TB samples coming to the 
laboratory per day since one tissue culture plate is adequate for four samples. This 
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means the incubator space that would be needed by the many NRA tubes would be 
saved. Thus, a modestly sized incubator with less energy consumption could be 
adequate for the MODS assay. Furthermore, MODS uses much less drugs in the 
assays than NRA, and this may reduce the cost of testing. The WHO in July 2010 
recommended the use of NRA, MODS and colorimetric assays as non-commercial 
susceptibility tests for MDR-TB in RLSs. Data from this research program represents 
more recent experience with these assays in a typical RLS, and it may be helpful in 
guiding RLSs on which tests to select for routine MDR-TB screening.   
 
On the other hand, the commercially available Genotype® MTBDRplus, which was the 
most rapid assay, and which is one of the line probe assays recommended by WHO can 
be used in the RLSs where resources permit. Being a highly sensitive and specific assay 
for R resistance, it remains an important test for rapid screening of smear positive 
patients for MDR-TB (within 1-2 days of TB diagnosis). Patients can then be managed 
appropriately as further testing is ongoing. This would help to minimize patient 
mismanagement and the uncontrolled spread of MDR-TB. Whereas training, 
supervision and adherence to protocols in molecular biology remains a priority, more 
recent studies in Africa indicate that molecular testing is becoming feasible in RLSs 
(96, 104, 124) . 
 
Lastly, Uganda has been granted permission by the Green Light Committee (GLC) of 
the World Health Organization (WHO) to treat patients with MDR-TB using second 
line anti-TB drugs, and the isolation ward has been earmarked at the Mulago National 
referral Hospital. Therefore, results from this study are timely, and will be directly 
applicable for rapid screening of TB patients for MDR-TB not only among patients 
from Uganda, but from neighboring countries in the lake Victoria region (Uganda, 
Kenya, Tanzania, Rwanda, Burundi, Democratic Republic of Congo (DRC), Ethiopia, 
Somalia and Sudan).  
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